SOLVE FSHD Announces Appointment of Executive Director Dr. Eva Chin and Venture-Philanthropic Funding Structure
VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Following SOLVE FSHD’s recent acclaimed launch, the organization is pleased to formally announce the appointment of Dr. Eva Chin as the Executive Director. SOLVE FSHD’s Founder, Chip Wilson, has personally committed USD100 million to find a cure for facioscapulohumeral muscular dystrophy (FSHD), a rare disease he was diagnosed with at the age of 32. As the inaugural Executive Director for SOLVE FSHD, Dr. Chin will be responsible for aligning the organization’s goals with the expertise of researchers, scientists and companies to promote and fund the discovery and development of new therapies for FSHD.
“Dr. Chin’s experience and specialization in rare neuromuscular diseases add immense value to our organization. We are excited to gain her expertise and guidance to achieve the organization’s goal of finding a cure for FSHD by December 2027,” says Chip Wilson, SOLVE FSHD Founder. He added, “Within just a few weeks of the organization’s launch, SOLVE FSHD has received a tremendous response to the call for qualified grant applications and new therapeutic technologies, which will be reviewed under Dr. Chin’s leadership. In addition, she has worked tirelessly to build strong industry alliances for SOLVE FSHD, closely assessed the exciting projects to fund and facilitated collaborative funding opportunities across the academic and industry sectors in FSHD research and drug development.”
Dr. Chin obtained her Ph.D. in Physiology from the University of Waterloo in Canada and completed post-doctoral training at the University of Sydney, Australia and U.T. Southwestern Medical Center in Dallas, focusing on intracellular calcium in muscle fatigue and transcriptional regulation of gene expression in muscle fibre type determination and muscle plasticity.
“I am honoured to join the Solve FSHD team, supporting Chip and the Wilson Family in our mission to improve the quality of life for those affected by rare neuromuscular diseases by funding qualified research projects and pre-clinical and clinical research that will accelerate finding a cure for FSHD,” says Dr. Eva Chin, Solve FSHD Executive Director.
Dr. Chin’s career has spanned the academic and pharmaceutical industries, with previous positions at Pfizer, the University of Maryland, MyoTherapeutics, Cytokinetics and NMD Pharma. While at Pfizer, Eva shifted her career from academic research focusing on cellular and molecular mechanisms of muscle function to discovering and developing muscle-targeted therapies. Over the past five years, she has led the nonclinical development of numerous drug candidates in clinical trials for ALS, SMA, myasthenia gravis and hypertrophic cardiomyopathy.
Under Dr. Chin’s guidance, Solve FSHD’s venture-philanthropic funding model will strategically utilize Wilson’s monetary commitment to support the initial grants, investments in early-stage companies focused on FSHD and to incentivize pharmaceutical companies in the neuromuscular disease space to increase their focus on FSHD. The venture philanthropy model will enable the organization to be financially self-sustainable through return on investments. The investments in viable, albeit high-risk, research opportunities may generate a continued re-investment stream into the organization to further support grant funding initiatives.
“To take advantage of recent advances in genetic therapeutics, SOLVE FSHD constructed a creative funding platform to facilitate the development of treatments that rapidly slow, stop or even reverse weakness in FSHD,” said Dr. John Day, MD, Ph.D., Director of Stanford University’s Neuromuscular Medicine program. “Having someone with Dr. Eva Chin’s experience and capabilities join SOLVE FSHD is critical to establishing the scientifically rigorous program needed to define and validate safe and effective treatments as quickly as possible,” says Dr. John Day, MD, Ph.D., Neuromuscular Medicine, Stanford Neuroscience Health Center.
About Solve FSHD
Solve FSHD is funding innovative biotech and biopharma research and development activities that accelerate novel treatments of Facioscapulohumeral muscular dystrophy (FSHD) treatment. It is fully funded and created by Canadian entrepreneur and philanthropist Chip Wilson. The founder of yoga-inspired athletic apparel company Lululemon Athletica inc. has been living with FSHD for the last three decades of his life. He has committed $100 million of his own money to create SOLVE FSHD and kick-start funding into projects that fit the organization’s mission: accelerate research into new therapies and find a cure for the disorder by 2027.
If you have FSHD and want to find out about clinical trials or be included in the FSHD registry, please see SOLVE FSHD’s website - https://solvefshd.com/
For media inquiries or to request a media interview, please contact:
Kamran Shaikh, Account Director
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0e87aacb-92f4-4723-9e7e-e24021cff5f7To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 202224.5.2022 22:05:00 CEST | Press release
ERYTECHAnnounces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022. ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2 rue Scribe, 75009 Paris (FRANCE). Shareholders may participate in the General Meeting as follows: Attend in person; Voting by mail or by internet on the secure voting platform Votaccess; or Give a proxy to any individual or legal entity of their choice, under the applicable legal and regulatory conditions, or give a proxy to the Chairman of the Shareholde
Data Quality Leaders Unite Around Alation’s ‘Open Data Quality Initiative’24.5.2022 16:50:06 CEST | Press release
Alation 2022.2 includes new framework that drives freedom of choice and flexibility for organisations; delivers quality data to data consumers at point of consumption REDWOOD CITY, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Alation Inc., the leader in enterprise data intelligence solutions, announced that leading data quality and data observability providers such as Acceldata, Anomalo, Bigeye, Experian, FirstEigen, Lightup, and Soda, and industry partners including Capgemini and Fivetran, have joined Alation in support of its newly launched Alation Open Data Quality Initiative for the Modern Data Stack. The program provides customers with the freedom of choice and flexibility when selecting the best data quality and data observability vendors to fit the needs of their modern, data-driven organisations. The Open Data Quality Initiative was designed to accelerate data governance and access to trusted self-service analytics for the broadest range of data consumers. Data quality is a top pri
PubMatic Launches Connect to Streamline Data Activation on the Sell-Side24.5.2022 16:00:00 CEST | Press release
New Fully Integrated, Omnichannel Addressability Solution Helps Buyers Target Audiences with Any Data Currency NO-HEADQUARTERS/REDWOOD CITY, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced the launch of Connect, a comprehensive and fully integrated platform to enable media buyers to seamlessly connect with their target audiences across the open internet. Connect is one of the only unbiased addressability offerings that combines many of the preferred signal approaches into one platform, including known identity, first- and second-party data, contextual signals, seller-defined audiences, and modeled audiences. The solution enables brands and media buyers to activate a portfolio approach to addressability to improve ad relevance while respecting consumer privacy, well ahead of the ecosystem's transition away from the third-party cookie. Connect builds on the mom
JETEX AND VOLOCOPTER REVOLUTIONIZE URBAN AIR MOBILITY MODEL24.5.2022 15:20:31 CEST | Press release
At EBACE 2022, Jetex and Volocopter sign a milestone strategic partnership agreement to define a safe and sustainable model of urban air mobility (UAM) Dubai, United Arab Emirates, May 24, 2022 (GLOBE NEWSWIRE) -- Jetex, an award-winning leader in private aviation, and Volocopter, a pioneer in the world’s first-ever eVTOL suite of services, enter in a strategic partnership agreement to deploy and operate permanent, economically sustainable, and integrated UAM taxi take-off and landing infrastructure and services for passenger transportation. Recent technological advancements and the need for more affordable, rapid and sustainable travel are driving this trend forward. Both companies aim to launch operations from 2024. Miami, Singapore and Paris are the priority markets where Jetex already established its presence and where sustainable air taxi operations are being mapped for passenger transportation. Jetex and Volocopter are researching most popular routes in these markets to ensure se
Auriant Mining:s delårsrapport för Q1 2022 och online-konferens den 31 maj 202224.5.2022 15:20:21 CEST | Pressemelding
Auriant Mining AB har nöjet att meddela att Bolagets delårsrapport för Q1 2022 kommer att publiceras på tisdagen den 31 maj. Detta kommer att följas av ZOOM-konferens för analytiker och investerare med Danilo Lange (VD), Vladimir Vorushkin (Ekonomichef) and Petr Kustikov (Operativ chef), som kommer att presentera Auriant Mining:s resultat för Q1 2022 samt med en möjlighet att ställa frågor. Evenemanget börjar kl. 13:00 CET (13:00 Stockholm, 14:00 Moskva, 12:00 London). För att delta i ZOOM-konferensen tisdagen den 31 maj, vänligen skicka till e-post firstname.lastname@example.org följande uppgifter: e-post, namn, företagsnamn. Vi kommer att skicka konferens-ID och lösenord via mail. Om du har några frågor kan du skicka dem till e-post: email@example.com För mer information, vänligen kontakta: Danilo Lange, VD Tel: +7 495 109 02 82 E-post: firstname.lastname@example.org Företagsnamn: Auriant Mining AB Kortnamn: AUR ISIN-kod: SE0001337213 Webbplats: www.auriant.com Auriant Mining AB (AUR) är ett svenskt gruvbolag